Zenas files new $200M stock offering as obexelimab BLA review continuesNov 6FinancingobexelimabZenas BioPharma (USA), LLCUpdated
Zenas BioPharma refreshes at-the-market program with new $200 million prospectus supplementNov 6FinancingZenas BioPharma (USA), LLC
Zenas BioPharma reports Q2 2026 results, obexelimab BLA now accepted by FDAAug 13Quarterly updateobexelimabZenas BioPharma (USA), LLC